| abstract |
The invention discloses a malignant glioma CAR-T treatment vector based on an OCTS technology, which comprises a lentiviral backbone plasmid, a human EF1 α promoter (SEQ ID NO.14), an OCTS chimeric receptor domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor domain comprises a CD8leader chimeric receptor signal peptide (SEQ ID NO.15), a PDL1 single-chain antibody light chain VL (SEQ ID NO.16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO.17), an EGFRvIII single-chain antibody light chain VL (SEQ ID NO.18), an EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO.19), an antibody Inner Hinge Inner-Linker (SEQ ID NO.20), a single-chain antibody Inter-Linker (SEQ ID NO.21), a CD8Hinge chimeric receptor Hinge (SEQ ID NO.22), a CD8 trans-receptor chimeric Transmembrane region (SEQ ID NO.23), a TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and a glioma receptor co-stimulating factor constructing method thereof. |